ONCS Stock: OncoSec Medical Incorporated Stock Price, Analysis & Insights
Get live oncs stock price $0.28, comprehensive OncoSec Medical Incorporated stock analysis, charts, news, and expert forecast. Real-time oncs stock data and investment insights.
Loading chart...
Company Overview
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Company Information
- CEO
- Robert H. Arch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
Contact Information
- Website
- https://oncosec.com
- Address
- 24 North Main Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.00)
Business Model & Strategy
OncoSec Medical Incorporated operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Robert H. Arch, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
OncoSec Medical Incorporated competes in the Biotechnology within the broader Healthcare. With 1.7 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, OncoSec Medical Incorporated provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating OncoSec Medical Incorporated should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for OncoSec Medical Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for OncoSec Medical Incorporated
- ⚠Investors should consider how OncoSec Medical Incorporated fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.65M
P/E Ratio
-0.01
Beta
2.00
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.65M market capitalization
- Trading Volume: 51.30M shares traded today
- Price Range: 52-week range of $0.18 - $20.46
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for OncoSec Medical Incorporated
OncoSec Medical Incorporated (ONCS) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.65M, the company represents a significant player in its market. The stock is currently trading at $0.28 with a positivedaily change of 31.87%.
The company's 40 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.01, beta of 2.00, and 52-week price range from $0.18 to $20.46when evaluating investment opportunities.
Why Invest in OncoSec Medical Incorporated?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Robert H. Arch
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.